Genmab (GMAB)
(Delayed Data from NSDQ)
$25.64 USD
+0.16 (0.63%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $25.66 +0.02 (0.08%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GMAB 25.64 +0.16(0.63%)
Will GMAB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GMAB
GMAB or TECH: Which Is the Better Value Stock Right Now?
GMAB vs. TECH: Which Stock Is the Better Value Option?
GMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
Other News for GMAB
AbbVie, Genmab blood cancer therapy endorsed in EU
Genmab’s Epcoritamab Poised to Transform Lymphoma Treatment
Genmab gets CHMP opinion recommending marketing authorization of epcoritamab
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma